Having presented new data at last year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting – where the safety and efficacy of Novartis’ Kesimpta ...

Most people with multiple sclerosis (MS) have a type called relapsing-remitting MS (RRMS). It usually starts in your 20s or 30s. One study shows that people who began treatment when their first ...

There were only two comprehensive clinics in the world for TM until the University of Alabama ... Ph.D., a scientist in the department who studies multiple sclerosis, a disease similar to TM. Jezdimir ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Each person’s journey with multiple sclerosis (MS) is different ... you might meet your next best friend! MS World is run by volunteers who have MS or have provided care for someone with ...

Results of a world-first phase 3 trial for secondary progressive multiple sclerosis (MS), led by UCL researchers, have shown that the commonly used high-cholesterol drug simvastatin cannot slow ...

Multiple sclerosis may lead to mild short-term memory ... and then remembering them shortly after. A third possible mechanism that may affect memory in MS is retention, which is the ability ...

Cosmos Health (COSM) announced the filing of a patent application for treatment for multiple sclerosis, a disabling autoimmune disorder ...